
Maha H. Hussain, MB, ChB, professor of medicine and deputy director at Robert H. Lurie Comprehensive Cancer Center, discusses the current role of PARP inhibitors in clinical trials for treatment of patients with prostate cancer.

Published: June 8th 2018 | Updated: